BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 22285953)

  • 21. Nitric oxide synthase 1 is partly compensating for nitric oxide synthase 3 deficiency in nitric oxide synthase 3 knock-out mice and is elevated in murine and human cirrhosis.
    Biecker E; Neef M; Sägesser H; Shaw S; Koshy A; Reichen J
    Liver Int; 2004 Aug; 24(4):345-53. PubMed ID: 15287858
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Splanchnic hyposensitivity to glypressin in a haemorrhage/transfused rat model of portal hypertension: role of nitric oxide and bradykinin.
    Chu CJ; Wu SL; Lee FY; Wang SS; Chang FY; Lin HC; Chan CC; Lee SD
    Clin Sci (Lond); 2000 Dec; 99(6):475-82. PubMed ID: 11099389
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evidence for a functional role of angiotensin II type 2 receptor in the cardiac hypertrophic process in vivo in the rat heart.
    Lakó-Futó Z; Szokodi I; Sármán B; Földes G; Tokola H; Ilves M; Leskinen H; Vuolteenaho O; Skoumal R; deChâtel R; Ruskoaho H; Tóth M
    Circulation; 2003 Nov; 108(19):2414-22. PubMed ID: 14568903
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of nitric oxide and endothelin-1 in a portal hypertensive rat model.
    Tsugawa K; Hashizume M; Migou S; Kishihara F; Kawanaka H; Tomikawa M; Tanoue K; Sugimachi K
    Scand J Gastroenterol; 2000 Oct; 35(10):1097-105. PubMed ID: 11099065
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endothelin receptor blockers reduce shunting and angiogenesis in cirrhotic rats.
    Hsu SJ; Lin TY; Wang SS; Chuang CL; Lee FY; Huang HC; Hsin IF; Lee JY; Lin HC; Lee SD
    Eur J Clin Invest; 2016 Jun; 46(6):572-80. PubMed ID: 27091078
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cross-talk between AT(1) and AT(2) angiotensin receptors in rat anococcygeus smooth muscle.
    de Godoy MA; de Oliveira AM
    J Pharmacol Exp Ther; 2002 Oct; 303(1):333-9. PubMed ID: 12235268
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peroxisome proliferator-activated receptor alpha activation attenuated angiotensin type 1-mediated but enhanced angiotensin type 2-mediated hemodynamic effects to angiotensin II in the rat.
    Banks T; Oyekan A
    J Hypertens; 2008 Mar; 26(3):468-77. PubMed ID: 18300857
    [TBL] [Abstract][Full Text] [Related]  

  • 28. N omega-nitro-L-arginine administration corrects peripheral vasodilation and systemic capillary hypotension and ameliorates plasma volume expansion and sodium retention in portal hypertensive rats.
    Lee FY; Colombato LA; Albillos A; Groszmann RJ
    Hepatology; 1993 Jan; 17(1):84-90. PubMed ID: 8423045
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiotensin II-induced relaxation of anococcygeus smooth muscle via desensitization of AT1 receptor, and activation of AT2 receptor associated with nitric-oxide synthase pathway.
    de Godoy MA; de Oliveira AM; Rattan S
    J Pharmacol Exp Ther; 2004 Oct; 311(1):394-401. PubMed ID: 15178697
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hemodynamic and antifibrotic effects of losartan in rats with liver fibrosis and/or portal hypertension.
    Croquet V; Moal F; Veal N; Wang J; Oberti F; Roux J; Vuillemin E; Gallois Y; Douay O; Chappard D; Calès P
    J Hepatol; 2002 Dec; 37(6):773-80. PubMed ID: 12445418
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of bile duct-ligated rats with the nitric oxide synthase transcription enhancer AVE 9488 ameliorates portal hypertension.
    Biecker E; Trebicka J; Kang A; Hennenberg M; Sauerbruch T; Heller J
    Liver Int; 2008 Mar; 28(3):331-8. PubMed ID: 18290775
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Salviae miltiorrhizae ameliorates cirrhosis and portal hypertension by inhibiting nitric oxide in cirrhotic rats.
    Wang H; Chen XP; Qiu FZ
    Hepatobiliary Pancreat Dis Int; 2003 Aug; 2(3):391-6. PubMed ID: 14599946
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Angiotensin II type 2 receptor-mediated inhibition of norepinephrine release in isolated rat hearts.
    Sasaoka T; Egi Y; Tawa M; Yamamoto A; Ohkita M; Takaoka M; Maruyama T; Akira T; Matsumura Y
    J Cardiovasc Pharmacol; 2008 Aug; 52(2):176-83. PubMed ID: 18670361
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The beneficial effects of curcumin in cirrhotic rats with portal hypertension.
    Hsu SJ; Lee JY; Lin TY; Hsieh YH; Huang HC; Lee FY; Lin HC; Hou MC; Lee SD
    Biosci Rep; 2017 Dec; 37(6):. PubMed ID: 29162665
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Involvement of endogenous opioid peptides and nitric oxide in the blunted chronotropic and inotropic responses to beta-adrenergic stimulation in cirrhotic rats.
    Ebrahimi F; Tavakoli S; Hajrasouliha AR; Sadeghipour H; Dehghani M; Ahmadi SH; Dehpour AR
    Fundam Clin Pharmacol; 2006 Oct; 20(5):461-71. PubMed ID: 16968416
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Beneficial Effects of P2X7 Antagonism in Rats with Bile Duct Ligation-induced Cirrhosis.
    Tung HC; Lee FY; Wang SS; Tsai MH; Lee JY; Huo TI; Huang HC; Chuang CL; Lin HC; Lee SD
    PLoS One; 2015; 10(5):e0124654. PubMed ID: 25933224
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical usefulness of the angiotensin II receptor antagonist losartan in patients with portal hypertensive gastropathy.
    Wagatsuma Y; Naritaka Y; Shimakawa T; Kanako H; Keiichiro I; Shunichi S; Konno S; Katsube T; Ogawa K
    Hepatogastroenterology; 2006; 53(68):171-4. PubMed ID: 16608017
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Portosystemic collaterals are not prerequisites for the development of hepatic encephalopathy in cirrhotic rats.
    Hsin IF; Wang SS; Huang HC; Lee FY; Chan CY; Chang CC; Hsu CY; Lin HC; Lee SD
    J Chin Med Assoc; 2012 Jan; 75(1):3-9. PubMed ID: 22240529
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diabetes diminishes the portal-systemic collateral vascular response to vasopressin via vasopressin receptor and Gα proteins regulations in cirrhotic rats.
    Lee JY; Huo TI; Wang SS; Huang HC; Lee FY; Lin HC; Chuang CL; Lee SD
    PLoS One; 2013; 8(7):e67703. PubMed ID: 23874439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis.
    Schneider AW; Kalk JF; Klein CP
    Hepatology; 1999 Feb; 29(2):334-9. PubMed ID: 9918907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.